Amyotrophic Lateral Sclerosis and Motor Neuron Disease
Clinical research activity includes ALS with attention to disease progression, functional decline, and treatment effects in adult patients.
- Disease progression in amyotrophic lateral sclerosis
- Functional outcomes in motor neuron disease
- Therapeutic evaluation of AMX0035
The sponsor’s work in this area centers on neurological conditions marked by progressive loss of motor function and disability.
Progressive Supranuclear Palsy and Neurodegeneration
Research also extends to progressive supranuclear palsy, with interest in clinical measures of symptom burden and neurological deterioration.
- PSP clinical assessment
- Neurological progression markers
- Treatment response in neurodegenerative disease
This reflects involvement in disorders affecting movement, balance, eye control, and cognition.
Pharmacokinetics in Renal Impairment
Studies include participants with renal impairment to examine how treatment exposure changes in the setting of reduced kidney function.
- Renal function and drug handling
- Medication exposure in kidney impairment
- Comparative assessment in healthy participants
These investigations support understanding of treatment use across populations with altered renal clearance.
Pharmacokinetics in Hepatic Impairment
Additional research focuses on hepatic impairment, examining treatment behavior in individuals with compromised liver function alongside healthy volunteers.
- Liver function and medication exposure
- Hepatic impairment studies
- Safety considerations in altered metabolism
This area addresses how hepatic dysfunction may influence therapeutic handling and clinical use.
Healthy Volunteers and Clinical Reference Populations
Trials also involve healthy volunteers as reference participants for comparison with patients and individuals with organ impairment.
- Healthy participant comparisons
- Reference populations in clinical research
- Baseline evaluation of treatment exposure
These studies support interpretation of therapeutic findings across neurological and organ impairment settings.
